Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest says Bystolic exceeded 2008 predictions

Forest says Bystolic exceeded 2008 predictions

22nd April 2009

Forest’s Bystolic sold better last year than the company expected, it has stated.

In its first year on the market, the hypertension treatment achieved $69.2 million (47.2 million pounds), which the company’s chairman and chief executive officer Howard Solomon asserted was a stronger result than forecast.

He added 2008 had seen the approval of Savella for the management of fibromyalgia and Lexapro had also been permitted to help adolescents with major depressive disorder.

Looking ahead to next year, Mr Solomon asserted the firm would continue to develop its pipeline with six products currently in phase III clinical trials.

The business has access to many new compounds, which have been discovered and developed by other companies, he said.

“Forest is viewed as a highly desirable development and marketing partner, often precisely because of our size and past performance.”

Mr Solomon concluded the company would be able to deliver sales and earnings in 2010 if it continued to support its current marketed products and further developed its efforts to find additional compounds.

This week, Forest and Cypress Bioscience announced Savella would be available in pharmacies from April 28th.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.